The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALT | -41.45% | -65.41% | -19.13% | -98% |
| S&P | +14.5% | +93.32% | +14.09% | +179% |
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.01M | 0.0% |
| Gross Profit | -$0.03M | 55.4% |
| Gross Margin | -500.00% | 620.0% |
| Market Cap | $313.88M | -33.4% |
| Market Cap / Employee | $5.32M | 0.0% |
| Employees | 59 | 0.0% |
| Net Income | -$22.15M | 10.1% |
| EBITDA | -$22.89M | 14.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $183.15M | 220.4% |
| Accounts Receivable | $0.32M | -24.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.61M | 929.0% |
| Short Term Debt | $0.24M | -30.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.25% | 8.6% |
| Return On Invested Capital | -47.45% | -6.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$19.66M | -8.6% |
| Operating Free Cash Flow | -$19.65M | -8.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.86 | 3.84 | 2.93 | 2.12 | -22.29% |
| Price to Sales | 8393.47 | 25689.55 | 18886.94 | 15765.91 | 1267.18% |
| Price to Tangible Book Value | 2.86 | 3.84 | 2.93 | 2.12 | -22.29% |
| Enterprise Value to EBITDA | -12.08 | -15.44 | -10.53 | -6.47 | -44.08% |
| Return on Equity | -73.0% | -59.9% | -57.3% | -55.9% | -11.67% |
| Total Debt | $1.77M | $1.68M | $1.59M | $15.85M | 751.18% |
ALT earnings call for the period ending June 30, 2022.
ALT earnings call for the period ending March 31, 2022.
ALT earnings call for the period ending December 31, 2021.
ALT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
